Welcome to our dedicated page for Polyrizon Ltd. SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. filed an amended Form 20-F to correct Item 15 and reaffirm that its disclosure controls and procedures were effective as of December 31, 2025. Management also concluded that internal control over financial reporting was effective under the COSO 2013 framework, with no auditor attestation required due to emerging growth company status.
The report describes a cybersecurity-related business email compromise in October 2025 that caused a wire transfer of approximately $464,000 to the wrong account, and a second attempted fraud in December 2025 that was prevented. The company reports the incident did not have a material impact but may lead to additional investigation and remediation costs, and outlines new verification and cybersecurity measures adopted in response.
Polyrizon Ltd., an Israel-based biotech company, files its annual report on Form 20-F, describing a development-stage business focused on C&C nasal barrier products and a T&T nasal drug-delivery platform. The company has not generated product revenue and is heavily dependent on successful clinical development and regulatory approvals.
Polyrizon reports operating losses of $6.249 million and $1.302 million for the years ended December 31, 2025 and 2024, with an accumulated deficit of about $8.4 million. As of December 31, 2025, it had 1,608,266 ordinary shares outstanding, cash and cash equivalents of $1.3 million and bank deposits of $16.2 million.
The report highlights significant risks, including the expectation of continued losses, the need for substantial additional funding, dependence on patient enrollment and regulatory clearances in the United States and European Union, and heavy reliance on its novel C&C and T&T technologies. Polyrizon is an emerging growth company and foreign private issuer, using reduced reporting and extended transition periods for new accounting standards, which may make comparisons to other public companies more difficult.
Polyrizon Ltd. director Itzhaik Asaf filed an initial statement of beneficial ownership, detailing restricted ordinary share holdings. One grant covers 2 restricted ordinary shares that vest in 7 equal quarterly installments beginning on April 30, 2026, subject to continued service.
A second grant covers 3,646 ordinary shares, of which 521 are already vested and 3,125 restricted ordinary shares vest in 6 equal quarterly installments beginning on March 31, 2026, also contingent on continued service. Certain securities are held in the name of a trustee to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
Polyrizon Ltd. director Sidi Liat filed an initial ownership report showing direct holdings of 2 ordinary shares in one line and 3,646 ordinary shares in another. The 3,646 shares include 521 vested shares and 3,125 restricted shares that vest in six equal quarterly installments beginning on March 31, 2026, subject to continued service. Additional restricted ordinary shares vest in seven equal quarterly installments starting on April 30, 2026. Certain equity awards are held through a trustee to qualify for Israeli tax benefits under Section 102.
Polyrizon Ltd. Chief Science Officer Ron Eyal S filed an initial ownership statement showing his equity position in the company. He directly holds 1,459 ordinary shares, including 208 vested shares and 1,251 restricted ordinary shares that vest in six equal quarterly installments beginning on March 31, 2026, subject to continued service. He also holds options over 8, 10 and 4 ordinary shares, with exercise prices of 1018.3000, 1699.3000 and 1700.3000, expiring in 2028 and 2030.
Polyrizon Ltd. director Vinokur Yehonatan Zalman has filed an initial ownership report of the company’s ordinary shares. The filing shows he holds both fully vested and restricted ordinary shares granted under the Polyrizon Ltd. Amended and Restated Equity Incentive Plan.
According to the disclosure, 521 ordinary shares are already vested, while 3,125 restricted ordinary shares are scheduled to vest in six equal quarterly installments beginning on March 31, 2026, subject to his continued service. Additional restricted ordinary shares are set to vest in seven equal quarterly installments beginning on April 30, 2026, also contingent on continued service.
The filing notes that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, equity awarded under the plan must be registered in the name of a trustee, which affects how these holdings are formally recorded.
Polyrizon Ltd. director Carmel Liron filed an initial ownership report showing restricted ordinary share awards rather than new market transactions. Liron holds 2 restricted ordinary shares that vest in 7 equal quarterly installments beginning on April 30, 2026, subject to continued service. An additional 4,167 ordinary shares are reported, of which 1,042 are already vested and 3,125 are restricted shares vesting in 6 equal quarterly installments starting March 31, 2026, also contingent on continued service. Certain equity awards are held through a trustee to qualify for Israeli Section 102 tax benefits.
Polyrizon Ltd. Chief Technology Officer Tidhar Turgeman filed an initial ownership report showing direct holdings of ordinary shares and employee options. He holds 18 restricted ordinary shares, with 5 already vested and 13 vesting in 8 equal monthly installments on a quarterly basis beginning on March 30, 2026, subject to continued service. He also holds 20,417 restricted ordinary shares, with 2,917 vested and 17,500 vesting in 6 equal quarterly installments beginning on March 31, 2026, subject to continued service. In addition, he holds options over 12, 23 and 7 ordinary shares at exercise prices of 1018.3000, 1700.3000 and 26.1000, expiring between August 30, 2026 and November 29, 2028. Certain securities are held through a trustee to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
Polyrizon Ltd. director Adler Oz has filed an initial ownership report showing holdings of the company’s ordinary shares, mainly in the form of restricted stock awards. One grant covers 100 ordinary shares, of which 66 are vested and 34 will vest in eight equal monthly installments on a quarterly basis beginning on March 30, 2026, subject to continued service. A second grant covers 23,042 ordinary shares, with 3,292 already vested and 19,750 scheduled to vest in six equal quarterly installments beginning on March 31, 2026. Certain shares are held through a trustee structure designed to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
Polyrizon Ltd. director and Chief Executive Officer Tomer Izraeli filed an initial ownership report showing his equity position in the company. He holds options to purchase ordinary shares, covering 5 and 83 underlying shares at exercise prices of 1699.3000 and 1700.3000 per share, expiring in 2026 and 2028. He also directly holds ordinary shares, including 53 restricted shares with 17 already vested and 36 scheduled to vest in eight equal quarterly installments beginning on March 30, 2026, and 35,780 restricted shares with 5,780 vested and 30,000 vesting in six equal quarterly installments beginning on March 31, 2026, all subject to his continued service.